Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.

Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Frandsen CS, Forman JL, Wewer Albrechtsen NJ, Holst JJ, Pedersen-Bjergaard U, Madsbad S, Vilsbøll T, Andersen HU, Knop FK

The lancet. Diabetes & endocrinology2 Mar 2020Cited by 56 (Europe PMC)

PMID32135138DOI10.1016/s2213-8587(20)30030-9PepBankPUB-32135138

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, HbA1c change did not significantly differ between exenatide and placebo.
In plain wordsIn adults with type 1 diabetes, exenatide did not significantly improve HbA1c compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeHbA1c
Study
n = 108
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−3.2 mmol/mol
exenatide, 26 weeks
HbA1c change
−2.1 mmol/mol
placebo, 26 weeks
HbA1c estimated treatment difference
−1.1 mmol/mol
exenatide versus placebo, 26 weeks
HbA1c change
−0.3%
exenatide, 26 weeks
HbA1c change
−0.2%
placebo, 26 weeks
HbA1c estimated treatment difference
−0.1%
exenatide versus placebo, 26 weeks
Source sentences
Summary
HbA_1c changed by -3·2 mmol/mol (-5·0 to -1·4 [-0·3%, -0·5 to -0·1]) with exenatide and -2·1 mmol/mol (-3·7 to -0·6 [-0·2%, -0·3 to -0·1]) with placebo after 26 weeks (estimated treatment difference of -1·1 mmol/mol (-3·4 to 1·2 [-0·1%, -0·3 to 0·1]; p=0·36).
1 context sentence(design, population, supporting numbers)
Summary · context
patients with type 1 diabetes on multiple daily injection therapy aged 18 years and older
Report a problemFND-3213513802
02HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes, treatment discontinuations numbered 17 with exenatide and six with placebo.
In plain wordsIn adults with type 1 diabetes, more participants stopped exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTreatment discontinuations
Study
n = 108
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Treatment discontinuations
17 participants
exenatide group
Treatment discontinuations
6 participants
placebo group
Source sentences
Summary
Between Jan 4, 2017, and Jan 16, 2019, 108 participants were randomly assigned, 54 to exenatide and 54 to placebo; 23 participants discontinued treatment (17 in the exenatide group and six in the placebo group).
1 context sentence(design, population, supporting numbers)
Summary · context
patients with type 1 diabetes on multiple daily injection therapy aged 18 years and older
Report a problemFND-3213513801
03HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes, exenatide increased self-reported gastrointestinal adverse events versus placebo.
In plain wordsIn adults with type 1 diabetes, exenatide produced more reported digestive adverse events than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGastrointestinal adverse events
Study
n = 108
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Exenatide increased the number of self-reported gastrointestinal adverse events (primarily nausea [48 events among 37 patients with exenatide, nine with placebo among 9 patients]).
1 context sentence(design, population, supporting numbers)
Summary · context
patients with type 1 diabetes on multiple daily injection therapy aged 18 years and older
Report a problemFND-3213513803
04HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes, nausea comprised 48 events among 37 exenatide patients versus nine events among nine placebo patients.
In plain wordsIn adults with type 1 diabetes, nausea events were more frequent with exenatide than placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseNausea
Study
n = 108
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Nausea events
48 events
exenatide group
Nausea events
9 events
placebo group
Patients with nausea
37 patients
exenatide group
Patients with nausea
9 patients
placebo group
Source sentences
Summary
Exenatide increased the number of self-reported gastrointestinal adverse events (primarily nausea [48 events among 37 patients with exenatide, nine with placebo among 9 patients]).
1 context sentence(design, population, supporting numbers)
Summary · context
patients with type 1 diabetes on multiple daily injection therapy aged 18 years and older
Report a problemFND-3213513804
05HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes, two serious adverse events occurred with exenatide versus six with placebo, with none considered drug-related.
In plain wordsIn adults with type 1 diabetes, serious events numbered two with exenatide and six with placebo. None were considered drug-related.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSerious adverse events
Study
n = 108
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
10 μg three times daily · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Serious adverse events
2 events
exenatide group
Serious adverse events
6 events
placebo group
Source sentences
Summary
Two serious adverse events occurred in the exenatide group, and six occurred in the placebo group (none were considered to be related to the study drug).
1 context sentence(design, population, supporting numbers)
Summary · context
patients with type 1 diabetes on multiple daily injection therapy aged 18 years and older
Report a problemFND-3213513805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

CompletedPhase 2NCT03017352

Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases

Filip Krag Knopn = 108Dec 2016 to Jun 2019

Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 10 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.